Shanghai Fosun Pharmaceutical (Group) (XSSC:600196) - Stock Price, News & Analysis

600196 Stock Overview

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

600196 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	3/6
Past Performance	2/6
Financial Health	5/6
Dividends	3/6

Rewards

Price-To-Earnings ratio (31.5x) is below the CN market (31.9x)

Earnings are forecast to grow 28.94% per year

Analysts in good agreement that stock price will rise by 24.4%

Risk Analysis

Profit margins (4.9%) are lower than last year (9.6%)

Dividend of 1.14% is not well covered by cash flows

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Competitors

Zhejiang NHU

SZSE:002001

CN¥59.0b

Sichuan Kelun Pharmaceutical

SZSE:002422

CN¥54.0b

Beijing Tongrentang

SHSE:600085

CN¥58.1b

Dong-E-E-JiaoLtd

SZSE:000423

CN¥44.3b

Price History & Performance

Summary of all time highs, changes and price drops for Shanghai Fosun Pharmaceutical (Group)
Historical stock prices
Current Share Price	CN¥23.67
52 Week High	CN¥32.73
52 Week Low	CN¥20.38
Beta	0.67
1 Month Change	1.41%
3 Month Change	11.70%
1 Year Change	-25.85%
3 Year Change	-56.69%
5 Year Change	-10.68%
Change since IPO	22.01%

Recent updates

Shareholder Returns

	600196	CN Pharmaceuticals	CN Market
7D	2.1%	2.7%	1.2%
1Y	-25.8%	-10.9%	-12.6%

Return vs Industry: 600196 underperformed the CN Pharmaceuticals industry which returned -10.9% over the past year.

Return vs Market: 600196 underperformed the CN Market which returned -12.6% over the past year.

Price Volatility

Is 600196's price volatile compared to industry and market?
600196 volatility
600196 Average Weekly Movement	4.3%
Pharmaceuticals Industry Average Movement	7.1%
Market Average Movement	8.3%
10% most volatile stocks in CN Market	12.1%
10% least volatile stocks in CN Market	5.0%

Stable Share Price: 600196 has not had significant price volatility in the past 3 months.

Volatility Over Time: 600196's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1994	40,370	Deyong Wen	www.fosunpharma.com

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Fundamentals Summary

How do Shanghai Fosun Pharmaceutical (Group)'s earnings and revenue compare to its market cap?
600196 fundamental statistics
Market cap	CN¥56.62b
Earnings (TTM)	CN¥2.01b
Revenue (TTM)	CN¥40.69b

31.5x

P/E Ratio

1.6x

P/S Ratio

Is 600196 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
600196 income statement (TTM)
Revenue	CN¥40.69b
Cost of Revenue	CN¥21.50b
Gross Profit	CN¥19.19b
Other Expenses	CN¥17.18b
Earnings	CN¥2.01b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.75
Gross Margin	47.16%
Net Profit Margin	4.94%
Debt/Equity Ratio	57.2%

How did 600196 perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

36%

Payout Ratio

600196 Stock Overview

Rewards

Risk Analysis

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Competitors

SZSE:002001

CN¥59.0b

SZSE:002422

CN¥54.0b

SHSE:600085

CN¥58.1b

SZSE:000423

CN¥44.3b

Price History & Performance

Recent News & Updates

First quarter 2024 earnings released: EPS: CN¥0.23 (vs CN¥0.37 in 1Q 2023)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: EPS: CN¥0.89 (vs CN¥1.43 in FY 2022)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) announces an Equity Buyback for CNY 200 million worth of its shares.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) announces an Equity Buyback for CNY 200 million worth of its shares.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023

Recent updates

First quarter 2024 earnings released: EPS: CN¥0.23 (vs CN¥0.37 in 1Q 2023)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: EPS: CN¥0.89 (vs CN¥1.43 in FY 2022)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) announces an Equity Buyback for CNY 200 million worth of its shares.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) announces an Equity Buyback for CNY 200 million worth of its shares.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) acquired additional 40% stake in Shanghai Fujian Equity Investment Fund Management Co., Ltd. from Shanghai Fosun Health Industry Holding Company Limited for CNY 22.2 million.

Third quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.34 in 3Q 2022)

Jiangsu Xingsheng Xinhui Pharmaceutical Co., Ltd. Receives Approval from the National Medical Products Administration of China for the Clinical Trial of XS-03 Tablets

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that it expects to receive CNY 497.7664 million in funding

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces National Medical Products Administration Accepts New Drug Application of Cisplatin Injection

Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.42 in 2Q 2022)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q2, 2023 Results on Aug 29, 2023

Palatin Technologies, Inc.'s Vyleesi Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Approval for Drug Registration of Fosun Kite Biotechnology Co., Ltd

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Annual General Meeting, Jun 28, 2023

Full year 2022 earnings released: EPS: CN¥1.43 (vs CN¥1.85 in FY 2021)

BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China

Fosun Reportedly Planning Sale of Gland Pharma

China's Fosun Reportedly Said to Mull Sale of India's $3.6 Billion Gland Pharma

Less than half of directors are independent

Investor sentiment improved over the past week

Shandong Liancheng Precision Manufacturing Co., Ltd (SZSE:002921) completed the acquisition of 3.9858% stake in Shanghai Shen-li High Tech Co., Ltd. from Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) and Shanghai Fulian Technology Co., Ltd.

Third quarter 2022 earnings released

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q3, 2022 Results on Oct 28, 2022

Executive Vice Chairman recently bought CN¥391k worth of stock

Now 20% undervalued after recent price drop

Executive Chairman recently bought CN¥887k worth of stock

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: CN¥0.43 (vs CN¥0.64 in 2Q 2021)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q2, 2022 Results on Aug 29, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Appoints Wen Deyong as an Executive Director

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Executive Appointments

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Recommends Final Dividend for 2021, Dispatch of Cheques for the 2021 Final Dividend Payable on H Shares Is 4 July 2022

First quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.33 in 1Q 2021)

Less than half of directors are independent

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q1, 2022 Results on Apr 26, 2022

Investor sentiment improved over the past week

Insilico Medicine Achieves Its First Major Milestone in Fosun Pharma Collaboration with the Nomination of Preclinical Candidate for QPCTL

Investor sentiment deteriorated over the past week

Fosun Pharma and Insilico Medicine Announces A Strategic, Ai-Driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets

Third quarter 2021 earnings released: EPS CN¥0.42 (vs CN¥0.30 in 3Q 2020)

Tianjin Kingyork Group Co., Ltd. signed the Equity Transfer agreement to acquire an additional 25.0011% stake in Tianjin Pharmaceutical Group Co., Ltd. from Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) for CNY 1.4 billion.

Second quarter 2021 earnings released: EPS CN¥0.64 (vs CN¥0.43 in 2Q 2020)

Director Xiaoliang Xu has joined 4th company board

Director Xiaoliang Xu has joined 4th company board

Director Xiaoliang Xu has joined 4th company board

Director Xiaoliang Xu has joined 4th company board

Director Xiaoliang Xu has joined 4th company board

Director Xiaoliang Xu has joined 4th company board

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Sisram Medical (Tianjin) Limited completed the acquisition of Shanghai Foshion Medical System Co., Ltd. from Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) and Qianda (Tianjin) International Trading Co., Ltd.

Independent Non-Executive Director Xian Jiang has left the company

Independent Non-Executive Director Tin Yau Wong has left the company

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Receives from US FDA Regarding the Clinical Trial of FCN-159 Tablets